Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895391 | 0.90 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL586633 | 0.90 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL969838 | 0.90 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL190770 | 0.86 | KDM4E (0.38) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3713407 | 0.81 | — | — | |
| SCHEMBL2535091 | 0.81 | SMN1; SMN2 (0.37) | MAPTSMN1; SMN2MEN1KMT2AGAA | |
| SCHEMBL31623264 | 0.80 | HSD11B1 (0.33) | — | |
| SCHEMBL428708 | 0.80 | — | — | |
| SCHEMBL2847700 | 0.80 | HPGD (0.40) | SMN1; SMN2GAANPC1RAB9AALDH1A1 | |
| SCHEMBL3322339 | 0.80 | HPGD (0.40) | SMN1; SMN2GAANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117460729-A | Novel (highly) piperidinyl heterocycles as sigma ligands | 塔拉萨科技协会 | 2024-01-26 | — | — | CN | disclosed |
| CN-116406360-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115028619-A | SMYD inhibitors | EPIZYME股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-107072205-B | SMYD inhibitors | EPIZYME股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2022095971-A1 | SPIRO HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海医药集团股份有限公司 | 2022-05-12 | — | — | WO | disclosed |
| US-5650416-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5631268-A | ANTIALLERGENS, 5HT2 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5602147-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-02-11 | — | — | US | disclosed |
| US-5596003-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5541200-A | Piperidinyl thiacyclic derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5476861-A | Piperidinyl thiacyclic derivatives | MERRELL DOW PHARMACEURICALS INC. (US) | 1995-12-19 | — | — | US | disclosed |
| EP-0626968-A4 | — | — | 1995-01-04 | — | — | EP | disclosed |
| EP-0626968-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5371093-A | Piperidinyl thiacyclic derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-12-06 | — | — | US | disclosed |
| WO-1993016081-A1 | PIPERIDINYL THIACYCLIC DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | MAPT 3554/4885SMN1; SMN2 263/4885MEN1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.